Matsui S, Takahashi T, Oyanagi Y, Takahashi S, Boku S, Takahashi K, Furukawa K, Arai F, Asakura H
Third Department of Internal Medicine, Niigata University School of Medicine, Japan.
J Hepatol. 1997 Nov;27(5):843-53. doi: 10.1016/s0168-8278(97)80322-4.
BACKGROUND/AIMS: Fibronectin is a multifunctional glycoprotein and plays important roles in cell-to-cell or cell-to-matrix interaction. The molecular and functional diversity of fibronectin arises from alternative splicing of pre-mRNA at three variable regions, termed ED-A, ED-B and IIICS. Cellular fibronectin with ED-A and ED-B regions has different biological activities from plasma fibronectin lacking these regions. This study was aimed at investigating the type-specific expression of fibronectin in human liver diseases.
Immunohistochemistry with anti-total and anti-cellular fibronectin monoclonal antibodies, in situ hybridization with cDNA probes detecting common and ED-A regions and RT-PCR to amplify each variable region were performed in 35 specimens, including 4 control, 16 chronic hepatitis, 7 liver cirrhosis and 8 hepatocelular carcinoma.
In control liver, there were slight deposits of cellular fibronectin [ED-A(+)fibronectin] in portal areas. In chronic hepatitis, it was strongly deposited at the margin of the fibrously enlarged portal areas where new collagen fibers were formed. Cellular fibronectin was evenly and abundantly accumulated in fibrotic septa in liver cirrhosis, and in fibrotic septa and capsules of tumor nodules in hepatocellular carcinoma. In control liver, cellular fibronectin mRNA was localized in a few hepatocytes and non-parenchymal cells around central veins, and was increased in the same cell populations near fibrously enlarged portal areas as hepatic fibrosis progressed. In hepatocellular carcinoma, it was expressed in most hepatoma cells. Fibronectin mRNA with three variable regions was detectable by RT-PCR in control liver as well as in each disease group.
The expression of cellular fibronectin was increased in fibrotic human liver and hepatocellular carcinoma. In human liver, both non-parenchymal cells and hepatocytes participated together in cellular fibronectin production. In hepatocellular carcinoma, hepatoma cells were the main producer. Our results indicate that, in human liver, cellular fibronectin may participate in the hepatic fibrogenesis and in the malignant phenotypes of hepatocellular carcinoma.
背景/目的:纤连蛋白是一种多功能糖蛋白,在细胞间或细胞与基质的相互作用中发挥重要作用。纤连蛋白的分子和功能多样性源于前体mRNA在三个可变区(称为ED - A、ED - B和IIICS)的可变剪接。含有ED - A和ED - B区域的细胞纤连蛋白与缺乏这些区域的血浆纤连蛋白具有不同的生物学活性。本研究旨在调查纤连蛋白在人类肝脏疾病中的类型特异性表达。
在35个标本中进行了实验,包括4个对照、16例慢性肝炎、7例肝硬化和8例肝细胞癌,使用抗总纤连蛋白和抗细胞纤连蛋白单克隆抗体进行免疫组织化学,用检测常见区域和ED - A区域的cDNA探针进行原位杂交,并用RT - PCR扩增每个可变区。
在对照肝脏中,门静脉区有少量细胞纤连蛋白[ED - A(+)纤连蛋白]沉积。在慢性肝炎中,它强烈沉积在纤维性扩大的门静脉区边缘,此处有新的胶原纤维形成。细胞纤连蛋白均匀且大量地积聚在肝硬化的纤维间隔中,以及肝细胞癌的肿瘤结节的纤维间隔和包膜中。在对照肝脏中,细胞纤连蛋白mRNA定位于中央静脉周围的少数肝细胞和非实质细胞中,并且随着肝纤维化进展,在纤维性扩大的门静脉区附近的相同细胞群体中增加。在肝细胞癌中,它在大多数肝癌细胞中表达。通过RT - PCR在对照肝脏以及每个疾病组中均可检测到具有三个可变区的纤连蛋白mRNA。
人类纤维化肝脏和肝细胞癌中细胞纤连蛋白的表达增加。在人类肝脏中,非实质细胞和肝细胞共同参与细胞纤连蛋白的产生。在肝细胞癌中,肝癌细胞是主要生产者。我们的结果表明,在人类肝脏中,细胞纤连蛋白可能参与肝纤维化形成以及肝细胞癌的恶性表型。